ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

1:15PM-1:30PM: Abstract Number: 2580

Estrogen Modulates Neutrophil Biology: Implications for Autoimmunity

Abstracts: Innate Immunity (2579–2584)

1:15PM-1:30PM: Abstract Number: 2598

Keratinocyte-Secreted Leukemia Inhibitory Factor Counteracts Type I IFN-Induced Antigen-Presenting Phenotype in Melanocytes: Utility in Cutaneous Lupus Skin

Abstracts: Systemic Lupus Erythematosus – Etiology and Pathogenesis (2597–2602)

1:15PM-1:30PM: Abstract Number: 2592

Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596)

1:30PM-1:45PM: Abstract Number: 2581

From Skin to Kidney: Neutrophil-Mediated Crosstalk Links Cutaneous Injury to Renal Inflammation and Vascular Remodeling in Lupus

Abstracts: Innate Immunity (2579–2584)

1:30PM-1:45PM: Abstract Number: 2599

Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites

Abstracts: Systemic Lupus Erythematosus – Etiology and Pathogenesis (2597–2602)

1:30PM-1:45PM: Abstract Number: 2575

Influenza and COVID-19 Vaccination Uptake Among Women with Systemic Rheumatic Diseases in New York City Assessed Between 2022 and 2024

Abstracts: Infection-related Rheumatic Disease (2573–2578)

1:30PM-1:45PM: Abstract Number: 2587

Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590)

1:30PM-1:45PM: Abstract Number: 2569

Performance of the PREVENT Heart Failure General Population Risk Score in Patients with Rheumatoid Arthritis

Abstracts: Epidemiology & Public Health II (2567–2572)

1:30PM-1:45PM: Abstract Number: 2593

Single Switch from Reference Denosumab to TVB-009 in Women with Postmenopausal Osteoporosis: Analysis of the Phase 3, Randomized, Double-Blind, Multinational, Multicenter Study

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596)

1:45PM-2:00PM: Abstract Number: 2570

Accelerometer-derived ‘weekend warrior’ physical activity, genetic susceptibility, and incident rheumatoid arthritis: a prospective cohort study

Abstracts: Epidemiology & Public Health II (2567–2572)

1:45PM-2:00PM: Abstract Number: 2594

Comparing Immunogenicity Between TVB-009 and Reference Denosumab in Healthy Adults and Participants with Postmenopausal Osteoporosis

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596)

1:45PM-2:00PM: Abstract Number: 2600

Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution

Abstracts: Systemic Lupus Erythematosus – Etiology and Pathogenesis (2597–2602)

1:45PM-2:00PM: Abstract Number: 2582

Inflammatory Cell Death and Impaired Efferocytosis Drive Monocyte and Macrophage Dysfunction in VEXAS Syndrome.

Abstracts: Innate Immunity (2579–2584)

1:45PM-2:00PM: Abstract Number: 2576

Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time

Abstracts: Infection-related Rheumatic Disease (2573–2578)

1:45PM-2:00PM: Abstract Number: 2588

Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].